west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "哌甲酯" 4 results
  • A Meta-analyses Comparing Atomoxetine with Methylphenidate for Treatement of Children with Attention- Deficit/ Hyperactivity Disorder

    Objective To assess atomoxetine and methylphenidate therapy for attention- deficit/ hyperactivity disorder (ADHD) .Methods We electronically searched the Cochrane Library (Issue 2, 2008), PubMed (1970 to 2008), MEDLINE (1971 to 2008), EMbase (1971 to 2008), Medscape (1990 to 2008), CBM (1978 to 2008), and NRR (1950 to 2008). We also hand-searched some published and unpublished references. Two independent reviewers extracted data. Quality was assessed by the Cochrane Reviewer’s Handbook 4.0. Meta-analysis was conducted by The Cochrane Collaboration’s RevMan 4.2.8 software. Results We finally identified 3 randomized controlled trials that were relevant to the study. Treatment response (reducing ADHD-RS Inattention subscale score) was significantly greater for patients in the methylphenidate group than in the atomoxetine group with WMD= – 1.79 and 95%CI – 2.22 to 1.35 (Plt;0.000 01). There was no statistical difference in other outcome measures between two groups (Pgt;0.05). Conclusions The effectiveness and tolerance of methylphenidate and atomoxetine are similar in treatment of ADHD. Further large randomized, double blind, placebocontrolled trials with end-point outcome measures in long-term safety and efficacy are needed.

    Release date:2016-09-07 02:09 Export PDF Favorites Scan
  • Preparation and in vitro Release Behavior of Methylphenidate Hydrochlori Desustained-release Capsules

    目的 制备一种盐酸哌甲酯(MPH)缓释微丸胶囊剂,并与进口控释片专注达?体外释放情况进行比较研究。 方法 利用流化床包衣技术制备一种含有3种不同释药速率微丸的MPH缓释微丸胶囊剂:将部分载药微丸包保护层后制成速释微丸;以乙基纤维素(Surelease?)为缓释材料制备单层缓释微丸;通过内包溶胀层(欧巴代-7006,主成分为低黏度羟丙基甲基纤维素(HPMC),外加控释层制备具有时滞的双层择时缓释微丸。在模拟胃肠道pH值介质中比较自制胶囊剂与控释片的体外释药情况。 结果 载药微丸实际载药量6.85%。单层缓释微丸包衣增重14%;双层择时缓释微丸溶胀层包衣增重16%,控释层包衣增重22%,时滞约3.5 h。3种微丸按以下比例混合后装胶囊:速释微丸含MPH 22%,单层缓释微丸含MPH 39%,双层择时缓释微丸含MPH 39%。该胶囊剂1 h释放可达25%,4 h释放约50%,12 h释放>95%。两制剂在模拟胃肠道介质中的释放曲线相似。 结论 制备出一种由3种微丸组成的,能连续12 h释药的MPH缓释微丸胶囊剂,其工艺简单,与进口控释片专注达?有相同的体外释放效果。

    Release date:2016-09-07 02:33 Export PDF Favorites Scan
  • Clinical Efficacy of Sensory Integration Training Combined with Methylphenidate Hydrochloride on Attention Deficit Hyperactivity Disorder in Children

    ObjectiveTo observe the effect of sensory integration training combined with methylphenidate hydrochloride on attention deficit hyperactivity disorder (ADHD). MethodsThe clinical data of 96 patients with ADHD diagnosed between January 2009 and March 2013 were retrospectively analyzed. The patients were divided into two groups by the table of random number. The trail group (n=48) received the combination therapy of sensory integration training combined with methylphenidate hydrochloride; while the control group (n=48) only received the medication of methylphenidate hydrochloride. The scores of sensory integration ability rating scale, integrated visual and auditory continuous performance test (IVA-CPT), Conner's behavior rating scale, Chinese Wechsler Intelligence Scale for Children (C-WISC) and adverse reactions were observed and compared between the two groups. ResultsThe scores of the sensory integration ability rating scale, FRCQ, FAQ (IVA-CPT), PIQ, VIQ, FIQ, C factor (C-WISC) in both of the two groups were significantly higher after the therapy; while the scores of the study, behavior, somatopsychic disturbance, impulsion, hyperactivity index and anxiety factor significantly decreased after the treatment (P<0.05). Compared with the control group, the trial group's scores of sensory integration ability rating scale, IVA-CPT, Conner's behavior rating scale, C-WISC were improved obviously, and the adverse reactions were significantly less (P<0.05). ConclusionThe sensory integration training combined with methylphenidate hydrochloride is sage and effective on children with attention deficit hyperactivity disorder.

    Release date: Export PDF Favorites Scan
  • 癫痫患儿注意缺陷多动障碍筛查、诊断和管理的系统评价:国际抗癫痫联盟儿科委员会共病工作组共识

    注意缺陷多动障碍(Attention-deficit/hyperactivity disorder,ADHD)是癫痫患儿一种常见且富有挑战的共患病。国际抗癫痫联盟(ILAE)儿科委员会共病工作组发现,关键问题在于识别和管理癫痫患儿中的 ADHD。对支持这些问题的方法的证据进行了系统评价,并根据美国神经病学学会实践参数的标准进行了整理和分级。遵循系统评价和 Meta 分析优先报告的条目(Preferred Reporting Items for Systematic Reviews and Meta-Analyses,PRISMA)要求,使用 PROSPERO 注册 (CRD42018094617)。与女性癫痫患儿相比,男性患儿无更高的共患 ADHD 风险(Level A)。孕期使用丙戊酸钠与子代注意力不集中和多动相关(1 项 I 级研究),且有智力和发育障碍的患儿合并 ADHD 的风险更高(A 级)。起病年龄对是否合并 ADHD 的影响尚不明确(U 级),但是发作控制欠佳的患儿合并 ADHD 的风险更高(B 级)。ADHD 的筛查应该从 6 岁或者明确诊断时开始,并且每年筛查一次(U 级),在抗癫痫药物调整后也应该重新评估(U 级)。ADHD 的诊断应该由受过 ADHD 专业培训的医务工作者参与(U 级)。支持使用优势和困难问卷筛查工具(B 级)。强烈建议有学习障碍的癫痫患儿进行正式的认知测试(U 级)。多药治疗的患儿出现行为问题的比例较单药治疗者更高(C 级)。丙戊酸钠可以加剧失神发作患儿的注意力集中障碍(A 级)。哌甲酯在癫痫患儿中耐受性及疗效均良好(B 级)。支持阿托莫西汀耐受性好的证据尚有限(C 级)。多学科参与过渡期和成人 ADHD 的诊治至关重要(U 级)。总之,虽然可以对一些研究问题提出建议,但这项系统评价强调了开展更全面、更有针对性的大样本前瞻性研究的必要性。

    Release date:2019-11-14 10:46 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content